copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
A Study of the S-1 or Capecitabine as First-line Regimen in Patients . . . Abstract Objectives: To compare the 2-year overall survival (OS) rate and safety between patients using S-1 and capecitabine in the first-treatment of metastatic colorectal cancer in the real clinical setting Methods: In this retrospective cohort study, patients satisfying the following criteria were identified from 10 centers in China The 2-year OS rate and safety were assessed
Clinicopathologic features and treatment efficacy of patients . . . - PubMed Clinicopathologic features and treatment efficacy of patients with BRAF V600E-mutated metastatic colorectal cancer: a multi-center real-world propensity score matching study 1 Department of Colorectal Cancer Center, West China Hospital of Sichuan University, 37 Guoxue The relative efficacy of first-line FOLFOXIRI triplet chemotherapy or
Metastatic Colorectal Cancer. First Line Therapy for . . . - PubMed Colorectal cancer (CRC) is a commonly diagnosed malignancy The prognosis of patients with unresectable, metastatic colorectal cancer (mCRC) is dismal and medical treatment is mainly palliative in nature Although chemotherapy remains the backbone of treatment, the landscape is changing with the und …
Disease characteristics and treatment patterns of Chinese patients with . . . Background Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients The current study is aimed to gain a real-world perspectives of CRC patients in China Methods Using electronic medical records of sampled patients between 2011 and 2016 from 12 hospitals in China, a retrospective cohort study was conducted to
Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and . . . This real-world study evaluated consecutive patients treated with the XELOXIRI regimen as first-line chemotherapy for APC at a national cancer center in China from August 2019 to June 2024 Treatment efficacy was assessed using the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS), and safety was assessed
Treatment of metastatic colorectal cancer with BRAF V600E . . . - PubMed Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China Eur J Surg Oncol 2023 Nov;49(11) :106981 doi The benefit of metastasectomy remains unclear, and the optimal first-line treatment is controversial This study aimed to describe the prognosis of BRAF V600E mutant-mCRC, analyze the
Disease characteristics and treatment patterns of Chinese patients with . . . Background: Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients The current study is aimed to gain a real-world perspectives of CRC patients in China Methods: Using electronic medical records of sampled patients between 2011 and 2016 from 12 hospitals in China, a retrospective cohort study was conducted to
Third-line treatment patterns and clinical outcomes for metastatic . . . Colorectal cancer (CRC) is the third most commonly diagnosed tumors and the second contributor to cancer-related mortality worldwide 1 The latest progress in the multidisciplinary treatment has greatly improved the survival rate, but most patients with metastatic CRC (mCRC) are still incurable Clinical factors such as the primary tumor location, and molecular markers including the RAS RAF
Real-world treatment patterns and clinical outcomes for chemotherapy . . . Colorectal cancer (CRC) is the third most diagnosed cancer and the third leading cause of death in the United States (US) [1] It is estimated that approximately 20% of newly diagnosed CRC is metastatic at initial presentation [2] and that 70% of patients with CRC at initial presentation develop metastasis [3] DNA mismatch repair is a molecular process that helps maintain genomic stability by